These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 32394723

  • 1. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression.
    Morrison CS, Hofmeyr GJ, Thomas KK, Rees H, Philip N, Palanee-Phillips T, Nanda K, Nair G, Onono M, Mastro TD, Lind M, Heffron R, Edward V, Deese J, Beksinska M, Beesham I, Stringer JSA, Baeten JM, Ahmed K, ECHO Trial Team.
    AIDS Res Hum Retroviruses; 2020 Aug; 36(8):632-640. PubMed ID: 32394723
    [Abstract] [Full Text] [Related]

  • 2. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.
    Lancet; 2019 Jul 27; 394(10195):303-313. PubMed ID: 31204114
    [Abstract] [Full Text] [Related]

  • 3. Effects of depot medroxyprogesterone acetate, the copper IUD and the levonorgestrel implant on testosterone, sex hormone binding globulin and free testosterone levels: ancillary study of the ECHO randomized clinical trial.
    Hofmeyr GJ, Singata-Madliki M, Batting J, Balakrishna Y, Morroni C.
    BMC Womens Health; 2024 Mar 08; 24(1):167. PubMed ID: 38459552
    [Abstract] [Full Text] [Related]

  • 4. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
    Singata-Madliki M, Lawrie TA, Balakrishna Y, d'Hellencourt FC, Hofmeyr GJ.
    Reprod Health; 2021 Sep 29; 18(1):192. PubMed ID: 34587971
    [Abstract] [Full Text] [Related]

  • 5. Sexual behaviour among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Data from the ECHO randomized trial.
    Hofmeyr GJ, Singata-Madliki M, Batting J, Steyn P, Thomas KK, Issema R, Beesham I, Mbatsane E, Morrison C, Deese J, Smit J, Philip N, Palanee-Phillips T, Reddy K, Onono M, Mastro TD, Baeten JM, Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.
    PLoS One; 2024 Sep 29; 19(5):e0299802. PubMed ID: 38722832
    [Abstract] [Full Text] [Related]

  • 6. Contraceptive method preference and reasons for contraceptive discontinuation among women randomized to intramuscular depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant: Findings from Durban, South Africa.
    Beesham I, Bosman S, Beksinska M, Scoville CW, Smit J, Nanda K.
    Contraception; 2022 Apr 29; 108():37-43. PubMed ID: 34848180
    [Abstract] [Full Text] [Related]

  • 7. Safety and continued use of the levonorgestrel intrauterine system as compared with the copper intrauterine device among women living with HIV in South Africa: A randomized controlled trial.
    Todd CS, Jones HE, Langwenya N, Hoover DR, Chen PL, Petro G, Myer L.
    PLoS Med; 2020 May 29; 17(5):e1003110. PubMed ID: 32442189
    [Abstract] [Full Text] [Related]

  • 8. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: Findings from a randomised, multicentre, open-label trial.
    Beksinska M, Issema R, Beesham I, Lalbahadur T, Thomas K, Morrison C, Hofmeyr GJ, Steyn PS, Mugo N, Palanee-Phillips T, Ahmed K, Nair G, Baeten JM, Smit J.
    EClinicalMedicine; 2021 Apr 29; 34():100800. PubMed ID: 33898953
    [Abstract] [Full Text] [Related]

  • 9. Effects of Depot Medroxyprogesterone Acetate Intramuscular Injection, Copper Intrauterine Device and Levonorgestrel Implant Contraception on Estradiol Levels: An Ancillary Study of the ECHO Randomized Trial.
    Ryan R, Mussa A, Singtaa-Madliki M, Batting J, Balakrishna Y, Morroni C, Hofmeyr GJ.
    Front Glob Womens Health; 2022 Apr 29; 3():887541. PubMed ID: 35669313
    [Abstract] [Full Text] [Related]

  • 10. Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.
    Mugo NR, Stalter RM, Heffron R, Rees H, Scoville CW, Morrison C, Kourtis AP, Bukusi E, Beksinka M, Philip NM, Beesham I, Deese J, Edward V, Donnell D, Baeten JM, Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.
    Clin Infect Dis; 2022 Sep 10; 75(4):586-595. PubMed ID: 34910143
    [Abstract] [Full Text] [Related]

  • 11. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
    Yela DA, Monteiro IM, Bahamondes LG, Del Castillo S, Bahamondes MV, Fernandes A.
    Rev Assoc Med Bras (1992); 2006 Sep 10; 52(1):32-6. PubMed ID: 16622536
    [Abstract] [Full Text] [Related]

  • 12. Comparison of pregnancy incidence among African women in a randomized trial of intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (IUDs) or a levonorgestrel (LNG) implant for contraception.
    Onono M, Nanda K, Heller KB, Taylor D, Yacobson I, Heffron R, Kasaro MP, Louw CE, Nhlabasti Z, Palanee-Phillips T, Smit J, Wakhungu I, Gichangi PB, Mugo NR, Morrison C, Baeten JM, Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium.
    Contracept X; 2020 Sep 10; 2():100026. PubMed ID: 32577615
    [Abstract] [Full Text] [Related]

  • 13. Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
    Deese J, Philip N, Lind M, Ahmed K, Batting J, Beksinska M, Edward VA, Louw CE, Onono M, Palanee-Phillips T, Smit JA, Baeten JM, Donnell D, Mastro TD, Mugo NR, Nanda K, Rees H, Morrison C.
    Sex Transm Infect; 2021 Jun 10; 97(4):249-255. PubMed ID: 33208512
    [Abstract] [Full Text] [Related]

  • 14. Post-randomization Differences in Condomless Vaginal Sex Among Women Randomized to Intramuscular Depot Medroxyprogesterone Acetate Injections, a Copper Intrauterine Device or a Levonorgestrel Implant in the ECHO Trial.
    Deese J, Chen PL, Gao X, Heffron R, Hobbs M, Lapple D, Jaspan H, Miller A, Nair G, Onono M, Palanee-Phillips T, Reddy K, Steiner MJ.
    AIDS Behav; 2023 Mar 10; 27(3):978-983. PubMed ID: 36357806
    [Abstract] [Full Text] [Related]

  • 15. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
    Modesto W, de Nazaré Silva dos Santos P, Correia VM, Borges L, Bahamondes L.
    Eur J Contracept Reprod Health Care; 2015 Feb 10; 20(1):57-63. PubMed ID: 25160484
    [Abstract] [Full Text] [Related]

  • 16. A 3-year multicentre randomized controlled trial of etonogestrel- and levonorgestrel-releasing contraceptive implants, with non-randomized matched copper-intrauterine device controls.
    Bahamondes L, Brache V, Meirik O, Ali M, Habib N, Landoulsi S, WHO Study Group on Contraceptive Implants for Women.
    Hum Reprod; 2015 Nov 10; 30(11):2527-38. PubMed ID: 26409014
    [Abstract] [Full Text] [Related]

  • 17. Weight change at 12 months in users of three progestin-only contraceptive methods.
    Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF.
    Contraception; 2013 Oct 10; 88(4):503-8. PubMed ID: 23582238
    [Abstract] [Full Text] [Related]

  • 18. The Effect of Contraception on Genital Cytokines in Women Randomized to Copper Intrauterine Device, Depot Medroxyprogesterone Acetate, or Levonorgestrel Implant.
    Tanko RF, Bunjun R, Dabee S, Jaumdally SZ, Onono M, Nair G, Palanee-Phillips T, Harryparsad R, Happel AU, Gamieldien H, Qumbelo Y, Sinkala M, Scoville CW, Heller K, Baeten JM, Bosinger SE, Burgener A, Heffron R, Jaspan HB, Passmore JAS.
    J Infect Dis; 2022 Sep 13; 226(5):907-919. PubMed ID: 35263421
    [Abstract] [Full Text] [Related]

  • 19. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.
    Chinula L, Nelson JAE, Wiener J, Tang JH, Hurst S, Tegha G, Msika A, Ellington S, Hosseinipour MC, Mataya R, Haddad LB, Kourtis AP.
    Contraception; 2018 Sep 13; 98(3):193-198. PubMed ID: 29746813
    [Abstract] [Full Text] [Related]

  • 20. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
    Bahamondes L, Bottura BF, Bahamondes MV, Gonçalves MP, Correia VM, Espejo-Arce X, Sousa MH, Monteiro I, Fernandes A.
    Hum Reprod; 2014 Oct 10; 29(10):2163-70. PubMed ID: 25085802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.